LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: LY317615 may stop the growth of cancer cells by blocking the enzymes necessary for
cancer cell growth and by stopping blood flow to the tumor. Drugs used in chemotherapy use
different ways to stop tumor cells from dividing so they stop growing or die. Combining
LY317615 with capecitabine may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of combining LY317615 with capecitabine in
treating patients who have advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborators:
Eli Lilly and Company National Cancer Institute (NCI)